CTF1 and kidney disorder: With regard to kidney disease, CT‐1 administration is protective in rat models of acute kidney disease induced by either gentamicin (Quiros et al., 2016), contrast media (Quiros et al., 2013) or ischemia–reperfusion (Garcia‐Cenador et al., 2013, 2018) resulting in improved renal function and lower levels of pro‐inflammatory cytokines and leukocyte‐adhesion molecules.